跳转至内容
Merck
CN

SML4130

PFI-90

≥98% (HPLC)

别名:

2-Pyridinecarboxylic acid 2-(2-pyridinyl)hydrazide, KDM3B Inhibitor PFI-90, PAX3-FOXO1 transcriptional Inhibitor 90, N′-(Pyridin-2-yl)picolinohydrazide

登录 查看组织和合同定价。

选择规格

变更视图

关于此项目

经验公式(希尔记法):
C11H10N4O
化学文摘社编号:
分子量:
214.22
MDL number:
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Segment

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

N(NC(=O)c2ncccc2)c1ncccc1, O=C(C1=NC=CC=C1)NNC2=NC=CC=C2

InChI

1S/C11H10N4O/c16-11(9-5-1-3-7-12-9)15-14-10-6-2-4-8-13-10/h1-8H,(H,13,14)(H,15,16)

InChI key

GCZPXNWBXDWHKM-UHFFFAOYSA-N

Biochem/physiol Actions

selective KDM3B inhibitor, disrupts PAX3-FOXO1 mediated transcription in FP-RMS.

PFI-90 directly targets and binds to metal ions in KDMs′ active sites, showing a strong preference for KDM3B (KD = 7.68 μM) while demonstrating minimal effect on other histone demethylases like KDM1A, KDM4B, KDM5A, KDM6B, HDAC1, HDAC2, HDAC3, and PRMT5. This selectivity leads to increased methylation at H3K4 and H3K9, disrupting the transcription of PAX3-FOXO1 oncogene targets in fusion-positive rhabdomyosarcoma (FP-RMS). PFI 90 effectively inhibits growth in PAX3-FOXO1 positive RMS cell lines (SCMC, RH4, RH30) with EC50 = 0.4, 0.9 and 3.2 µM, respectively. PFI-90 suppresses PAX3-FOXO1 function, inducing apoptosis and reducing RNA Pol2 activity without affecting PAX3-FOXO1 protein levels or DNA binding. Its treatment hampers FP-RMS tumor growth in vivo, offering a promising therapeutic avenue by selectively targeting KDM3B to combat FP-RMS.


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库